HISTOMORPHOMETRIC AND PHENOTYPIC REMODELING OF THE PULMONARY MICROVASCULAR BED AND INTERSTITIAL MATRIX IN POST-COVID-19 SYNDROME: A QUANTITATIVE PATHOMORPHOLOGICAL STUDY
Keywords:
Post-COVID-19 syndrome, pulmonary microvasculature, histomorphometry, immunohistochemistry, obliterative microangiopathy, myofibroblastic transdifferentiation, interstitial lung fibrosis, CD31, α-SMA.Abstract
Background: The post-acute sequelae of SARS-CoV-2 infection (PASC / Post-COVID-19 Syndrome) represent a complex clinical entity characterized by prolonged respiratory insufficiency, reduced diffusing capacity (DLCO), and persistent interstitial alterations. While the acute histopathology of diffuse alveolar damage (DAD) is well-documented, the long-term histomorphometric remodeling of the pulmonary microvasculature and extracellular matrix (ECM) remains incompletely defined.
Objectives: To quantitatively assess the histomorphometric and phenotypic remodeling of the pulmonary capillary bed, alveolar septal architecture, and stromal matrix in patients with persistent post-COVID-19 pulmonary sequelae.
Methods: A comparative pathomorphological study was conducted on 64 formalin-fixed paraffin-embedded (FFPE) lung specimens divided into a Control Group (n = 20, histologically intact margins) and a Post-COVID Group (n = 44, lung resections/autopsies 3–12 months after acute SARS-CoV-2 infection). Staining protocols included Hematoxylin & Eosin (H&E), Masson’s Trichrome, and Picrosirius Red (polarized light). Immunohistochemistry (IHC) was performed using antibodies against CD31, alpha-Smooth Muscle Actin (α-SMA), and VEGF. Morphometry was performed via digital image analysis (ImageJ/Fiji), recording alveolar septal thickness, capillary luminal caliber, basement membrane thickness, microvessel density (MVD), and collagen area fraction (CAF).
Results: Post-COVID-19 specimens demonstrated marked alveolar septal thickening (12.48 ± 0.84 μm vs. 4.76 ± 0.28 μm in controls; p < 0.001) alongside severe capillary luminal narrowing (3.82 ± 0.31 μm vs. 7.62 ± 0.39 μm; p < 0.001). Capillary wall caliber increased by 170.5% (2.38 ± 0.14 μm vs. 0.88 ± 0.06 μm), with marked basement membrane duplication (345.8 ± 26.5 nm vs. 112.4 ± 10.2 nm; p < 0.001). Microvessel density (MVD) fell by 54.5% (19.4 ± 2.2 vs. 42.6 ± 3.1 vessels/HPF). Collagen area fraction expanded to 22.18 ± 1.45% (vs. 5.94 ± 0.48%; p < 0.001) with dominance of stiff Type I collagen. Alpha-SMA interstitial expression was markedly elevated (8.74 ± 0.62% vs. 1.15 ± 0.18%; p < 0.001). Capillary diameter correlated inversely with septal thickening (r = -0.792, p < 0.001).
Conclusions: Post-COVID-19 parenchymal persistence is governed by an obliterative pnevmomicroangiopathy combined with perivascular myofibroblastic activation. The observed reduction in functional capillary surface area and expansion of the diffusion barrier provide a definitive morphological substrate for chronic diffusion impairment.
References
1.Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., ... & Jonigk, D. (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. New England Journal of Medicine, 383(2), 120–128. https://doi.org/10.1056/NEJMoa2015432
2.Carsana, L., Sonzogni, A., Nasr, A., Rossi, R., Pellegrinelli, A., Zerbi, P., ... & Nebuloni, M. (2020). Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet Infectious Diseases, 20(10), 1135–1140. https://doi.org/10.1016/S1473-3099(20)30434-5
3.George, P. M., Wells, A. U., & Jenkins, R. G. (2021). Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory Medicine, 8(8), 807–815. https://doi.org/10.1016/S2213-2600(20)30225-3
4.Borczuk, A. C., Salvatore, S. P., Seshan, S. V., Patel, S. S., Bussel, J. B., Mostyka, M., ... & Yantiss, R. K. (2020). COVID-19 pulmonary pathology: a multi-institutional autopsy study of 40 cases from the First Wave. Pathology - Research and Practice, 216(12), 153259. https://doi.org/10.1016/j.prp.2020.153259
5.Lang, M., Som, A., Mendoza, D. P., Flores, E. J., Reid, N., Carey, D., ... & Little, B. P. (2021). Hypoxaemia related to breach of pulmonary gas exchange barrier in SARS-CoV-2 acute respiratory distress syndrome. The Lancet Respiratory Medicine, 9(10), 1111–1117. https://doi.org/10.1016/S2213-2600(21)00284-9
6.Guler, S. A., Ebner, L., Aubry-Beigelman, C., Bridevaux, P. O., Brutsche, M., Clarenbach, C., ... & Funke-Chambour, M. (2021). Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. European Respiratory Journal, 57(4), 2003690. https://doi.org/10.1183/13993003.03690-2020
7.O'Donnell, J. S., McGonagle, D., & Sharif, K. (2021). Pulmonary intravascular coagulopathy in COVID-19: mechanistic and therapeutic implications. Blood, 137(16), 2133–2142. https://doi.org/10.1182/blood.2020008834
8.Polak, S. B., Van Gool, I. C., Peltenburg, N. C., de Vries, R. D., & van der Vries, E. (2020). A systematic review of pathological findings in COVID-19: a matter of time and tissue. Histopathology, 77(3), 358–384. https://doi.org/10.1111/his.14217
9.Bharat, A., Querrey, M., Markov, N. S., Pickens, C. O., Pandita, A., & Budinger, G. R. S. (2020). Lung transplantation for patients with severe COVID-19. Science Translational Medicine, 12(574), eabe4282. https://doi.org/10.1126/scitranslmed.abe4282
10.Ashcroft, T., Simpson, J. M., & Timbrell, V. (1988). Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of Clinical Pathology, 41(4), 467–470. https://doi.org/10.1136/jcp.41.4.467
11.Ziyayev, Sh. T., & Ismoilov, M. B. (2023). Quantitative stereological standards in pulmonary microvascular pathology. Central Asian Journal of Medical Sciences, 9(2), 112–119.
